Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more
Bayer Aktiengesellschaft (BAYA) - Net Assets
Latest net assets as of September 2025: €29.70 Billion EUR
Based on the latest financial reports, Bayer Aktiengesellschaft (BAYA) has net assets worth €29.70 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€104.21 Billion) and total liabilities (€74.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €29.70 Billion |
| % of Total Assets | 28.5% |
| Annual Growth Rate | 0.06% |
| 5-Year Change | 4.38% |
| 10-Year Change | N/A |
| Growth Volatility | 18.4 |
Bayer Aktiengesellschaft - Net Assets Trend (2016–2024)
This chart illustrates how Bayer Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bayer Aktiengesellschaft (2016–2024)
The table below shows the annual net assets of Bayer Aktiengesellschaft from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €32.05 Billion | -3.12% |
| 2023-12-31 | €33.08 Billion | -15.02% |
| 2022-12-31 | €38.93 Billion | +17.36% |
| 2021-12-31 | €33.17 Billion | +8.04% |
| 2020-12-31 | €30.70 Billion | -35.39% |
| 2019-12-31 | €47.52 Billion | +2.97% |
| 2018-12-31 | €46.15 Billion | +25.19% |
| 2017-12-31 | €36.86 Billion | +15.56% |
| 2016-12-31 | €31.90 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bayer Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €31.91 Billion | 100.00% |
| Total Equity | €31.91 Billion | 100.00% |
Bayer Aktiengesellschaft Competitors by Market Cap
The table below lists competitors of Bayer Aktiengesellschaft ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VeriSilicon Microelectronics Shanghai Co Ltd
SHG:688521
|
$10.01 Billion |
|
GAIL (INDIA) GDR/6 IR 10
F:GQI
|
$10.01 Billion |
|
Danone PK
OTCQX:DANOY
|
$10.03 Billion |
|
Plains All American Pipeline LP
NASDAQ:PAA
|
$10.04 Billion |
|
Rambus Inc
NASDAQ:RMBS
|
$9.98 Billion |
|
AECC Aviation Power Co Ltd
SHG:600893
|
$9.96 Billion |
|
Universal Health Services Inc
NYSE:UHS
|
$9.93 Billion |
|
Koc Holding AS
IS:KCHOL
|
$9.93 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bayer Aktiengesellschaft's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 32,927,000,000 to 31,908,000,000, a change of -1,019,000,000 (-3.1%).
- Net loss of 2,552,000,000 reduced equity.
- Dividend payments of 131,000,000 reduced retained earnings.
- Share repurchases of 16,000,000 reduced equity.
- Other factors increased equity by 1,680,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.55 Billion | -8.0% |
| Dividends Paid | €131.00 Million | -0.41% |
| Share Repurchases | €16.00 Million | -0.05% |
| Other Changes | €1.68 Billion | +5.27% |
| Total Change | €- | -3.09% |
Book Value vs Market Value Analysis
This analysis compares Bayer Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €43.79 | €9.90 | x |
| 2018-12-31 | €49.30 | €9.90 | x |
| 2019-12-31 | €48.18 | €9.90 | x |
| 2020-12-31 | €31.07 | €9.90 | x |
| 2021-12-31 | €33.61 | €9.90 | x |
| 2022-12-31 | €39.47 | €9.90 | x |
| 2023-12-31 | €33.52 | €9.90 | x |
| 2024-12-31 | €32.48 | €9.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bayer Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.48%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 3.47x
- Recent ROE (-8.00%) is below the historical average (1.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.94% | 9.69% | 0.57x | 2.71x | €1.50 Billion |
| 2017 | 19.93% | 20.95% | 0.47x | 2.04x | €3.66 Billion |
| 2018 | 3.69% | 4.28% | 0.31x | 2.75x | €-2.90 Billion |
| 2019 | 8.64% | 9.39% | 0.34x | 2.67x | €-642.70 Million |
| 2020 | -34.38% | -25.35% | 0.35x | 3.83x | €-13.55 Billion |
| 2021 | 3.03% | 2.27% | 0.37x | 3.64x | €-2.30 Billion |
| 2022 | 10.70% | 8.18% | 0.41x | 3.22x | €272.70 Million |
| 2023 | -8.93% | -6.17% | 0.41x | 3.53x | €-6.23 Billion |
| 2024 | -8.00% | -5.48% | 0.42x | 3.47x | €-5.74 Billion |
Industry Comparison
This section compares Bayer Aktiengesellschaft's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $643,784,392,000
- Average return on equity (ROE) among peers: -6.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bayer Aktiengesellschaft (BAYA) | €29.70 Billion | 14.94% | 2.51x | $9.98 Billion |
| EH3 (EH3) | $486.18 Million | -16.90% | 0.41x | $245.45 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $47.44 Billion | -10.03% | 1.21x | $241.99 Million |
| Otsuka Holdings Co. Ltd (OS1) | $1.88 Trillion | 7.87% | 0.40x | $26.35 Billion |